KTX-201 / Kymera Therap - LARVOL DELTA

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting (GlobeNewswire) - "Administration of a tool STAT3 degrader, KTX-201, led to molecular and cellular changes in the tumor microenvironment that were predictive of favorable responses to checkpoint inhibition. Consistent with these findings, KTX-201 sensitized these tumors to anti-PD1 treatment when administered in combination, leading to durable anti-tumor responses and development of long-term immunological memory."

Preclinical • Oncology

[VIRTUAL] Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma (ASH 2020) - "Collectively, our data demonstrate that significant STAT3 degradation for a limited time during dosing interval with KTX-201 in ALCL promotes early changes in key signaling nodes involved with proliferation and cytokine stimulation, followed by profound changes in apoptotic proteins. By integrating mechanistic biology with a deep understanding of PK/PD and efficacy, this study provides a foundation for the clinical development of STAT3 degraders using intermittent dosing regimen for treatment of PTCL and other STAT3-dependent heme malignancies."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • GZMB • STAT3